Yahoo Finance • yesterday
[Business on Wall Street in Manhattan] Pgiam/iStock via Getty Images * Absci (NASDAQ:ABSI [https://seekingalpha.com/symbol/ABSI]) shares traded higher on Thursday after J.P. Morgan initiated its coverage on the AI-driven biotech with a... Full story
Yahoo Finance • 23 days ago
Absci Corporation; Oracle; AMD Performance and scalability of Oracle Cloud Infrastructure AI infrastructure enables Absci to accelerate biologics design cycles and reduce costs AUSTIN, Texas and VANCOUVER, Washington, Sept. 11, 2025 (GLO... Full story
Yahoo Finance • last month
VANCOUVER, Wash. and NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today announced that world-renowned dermatologists Dr. Rodney... Full story
Yahoo Finance • last month
VANCOUVER, Wash. and NEW YORK, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced the company will be par... Full story
Yahoo Finance • 2 months ago
ABSCI CORP (NASDAQ:ABSI) REPORTS Q2 2025 EARNINGS: REVENUE MISSES ESTIMATES, MARKET REACTS NEGATIVELY Absci Corp (NASDAQ:ABSI [https://www.chartmill.com/stock/quote/ABSI]) reported its second-quarter 2025 financial results, revealing a re... Full story
Yahoo Finance • 2 months ago
* Absci press release [https://seekingalpha.com/pr/20198634-absci-reports-business-updates-and-second-quarter-2025-financial-and-operating-results] (NASDAQ:ABSI [https://seekingalpha.com/symbol/ABSI]): Q2 GAAP EPS of -$0.24 misses by $0.... Full story
Yahoo Finance • 2 months ago
Strengthened balance sheet raising approximately $64 million in gross proceeds in July 2025; cash, cash equivalents, and short-term investments now sufficient to fund operations into the first half of 2028 Expanded ongoing collaboration w... Full story
Yahoo Finance • 2 months ago
Almirall selects second target in AI Drug Creation collaborationExpanded collaboration builds on Absci’s successful de novo molecule design for difficult‑to‑drug targets in the first stage of the collaboration with Almirall BARCELONA, Spa... Full story
Yahoo Finance • 2 months ago
VANCOUVER, Wash. and NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today announced the company will re... Full story
Yahoo Finance • 2 months ago
In the latest trading session, Cathie Wood’s ARK ETFs made several significant transactions as part of their ongoing portfolio adjustments. On Friday, July 25th, 2025, the most substantial trade came from the purchase of 2,248,226 shares o... Full story
Yahoo Finance • 2 months ago
(RTTNews) - Absci Corporation (ABSI), a clinical-stage biopharma company leveraging generative AI for drug discovery, has priced an underwritten public offering of 16.67 million shares of its common stock at $3.00 per share. The offering... Full story
Yahoo Finance • 2 months ago
* Absci (NASDAQ:ABSI [https://seekingalpha.com/symbol/ABSI]) on Thursday said it has commenced an underwritten public offering of $50 million of shares of its common stock. * Absci also intends to grant the underwriters a 30-day option... Full story
Yahoo Finance • 2 months ago
VANCOUVER, Wash., July 24, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a clinical-stage biopharmaceutical company advancing potential breakthrough therapeutics designed with generative AI, announced today that it... Full story
Yahoo Finance • 3 months ago
SAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) , a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the retire... Full story
Yahoo Finance • 3 months ago
Absci Corporation Former Abbott executive who led the US launch and global expansion of Humira® adds three decades of commercial and clinical leadership expertise VANCOUVER, Wash., July 07, 2025 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI),... Full story
Yahoo Finance • 3 months ago
Investing.com - Morgan Stanley has initiated coverage on Absci Corp. (NASDAQ:ABSI) with an Overweight rating and a $7.00 price target. The company, currently valued at $343 million, has seen its stock demonstrate significant volatility w... Full story
Yahoo Finance • 5 months ago
Absci becomes clinical stage company with ABS-101, first AI-designed biologic for IBD, beginning Phase 1 trial Preclinical data for ABS-101 demonstrates high potency and potential for quarterly dosing, an improvement in efficacy and conve... Full story
Yahoo Finance • 6 months ago
VANCOUVER, Wash. and NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating re... Full story
Yahoo Finance • 7 months ago
Unveiled updates across proprietary pipeline and demonstrated new breakthroughs by AI platform at 2024 R&D Day Entered into collaboration with AMD, including $20 million strategic investment in Absci Achieved 2024 outlook for drug creati... Full story
Yahoo Finance • 7 months ago
VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating re... Full story